FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for suppressing replication of hepatitis C virus by inhibitor of catabolism enzymes of biogenic polyamines N,N’-bis(2,3-butadienyl)-1,4-butanediamine hydrochloride (MDL72.527). Compound inhibits reproduction of hepatitis C virus in micromolar concentrations in cultures of infected cells and in culture of cells carrying a subgenomic virus replicon.
EFFECT: method provides a wider range of antiviral agents.
1 cl, 3 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF N,N'-BIS-(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF SARS-COV-2 VIRUS | 2020 |
|
RU2761565C1 |
| PEGYLATED INTERFERON LAMBDA WITH HIGH BIOACCESSABILITY IN ORAL USE AND METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2678332C1 |
| ANTIVIRAL COMPOUND OF MULTIPLE ACTION, ITS COMPOSITION AND METHOD OF TREATING VIRAL DISEASES | 2012 |
|
RU2597150C2 |
| CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2375449C2 |
| RESISTANT MUTANTS OF PROTEASE NS3-NS4A HCV | 2004 |
|
RU2365624C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| PANGENOTYPIC NS5A PROTEIN INHIBITOR OF HEPATITIS C VIRUS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING AND USING | 2019 |
|
RU2723482C1 |
| PHARMACEUTICAL COMPOSITION OF N,N'-BIS(2,3-BUTADIENYL)-1,4-BUTANE-DIAMINE AND METHODS FOR USING IT | 2007 |
|
RU2448693C2 |
| RNA-CONDUCTOR St10 FOR USE IN THE HIGHLY SPECIFIC STREPTOCOCCUS THERMOPHILUS CRISPR / Cas9 (StCas9) NUCLEASES SYSTEM AND USE OF SAID RNA-CONDUCTOR AND StCas9 PROTEIN TO SUPPRESS HEPATITIS B VIRUS EXPRESSION IN THE HOST CELL AND FOR VIRAL DNA ELIMINATION FROM THE HOST CELL | 2018 |
|
RU2694396C1 |
| LIPOPHILIC POLYAMINES WITH ANTITUMOUR ACTIVITY | 2016 |
|
RU2618393C1 |
